Related Experiment Video

Updated: May 6, 2026

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis
10:40

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis

Published on: April 25, 2022

2.5K

Linking the SWI/SNF complex to prostate cancer

Ryan S Lee1, Charles W M Roberts

  • 1Department of Pediatric Oncology, Dana-Farber Cancer Institute, the Division of Hematology-Oncology, Boston Children's Hospital and the Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA.

Nature Genetics
|October 30, 2013
PubMed

Insights

Aggressive prostate tumors utilize SChLAP1, a long noncoding RNA, to drive cancer progression. SChLAP1 disrupts SNF5, a key component of the SWI/SNF chromatin-remodeling complex, promoting tumor growth.

Area of Science:

  • Cancer biology
  • Epigenetics
  • Prostate cancer research

Background:

  • The SWI/SNF chromatin-remodeling complex is frequently altered in various cancers.
  • Mutations in SWI/SNF genes are rare in prostate cancer.
  • Long noncoding RNAs (lncRNAs) play emerging roles in cancer development.

Purpose of the Study:

  • To investigate the role of SChLAP1, a lncRNA overexpressed in aggressive prostate tumors.
  • To determine the mechanism by which SChLAP1 contributes to prostate cancer progression.
  • To explore the interaction between SChLAP1 and the SWI/SNF complex.

Main Methods:

  • Analysis of SChLAP1 expression in prostate tumor samples.
  • Biochemical assays to study the interaction between SChLAP1 and SNF5.
  • Functional studies in prostate cancer cell lines to assess the impact of SChLAP1 on SWI/SNF activity and tumor growth.

Main Results:

  • SChLAP1 is highly expressed in aggressive prostate tumors.
  • SChLAP1 directly binds to and disrupts the function of SNF5, a core subunit of the SWI/SNF complex.
  • Disruption of SNF5 by SChLAP1 promotes prostate cancer cell proliferation and aggressiveness.

Conclusions:

  • SChLAP1 is a novel oncogenic driver in prostate cancer.
  • SChLAP1 promotes cancer by interfering with the SWI/SNF chromatin-remodeling complex via SNF5 disruption.
  • Targeting SChLAP1 or its interaction with SNF5 may offer new therapeutic strategies for aggressive prostate cancer.

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

5.8K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.5K

Related Concept Videos

Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
2.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
Assembly of Signaling Complexes01:30

Assembly of Signaling Complexes

Multiprotein signaling complexes are formed in a dynamic process involving protein-protein interactions at the cytoplasmic domain of transmembrane receptors or enzymatic and non-enzymatic proteins associated with the receptor. These complexes ensure the activation and propagation of intracellular signals that regulate cell functions.
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
4.7K
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
8.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K